| Entity | Document Type | Tax ID |
|---|---|---|
| Huntington's Disease Society of America | IRS Form 990 | 13-3349872 |
| Huntington's Disease Society of America Group | IRS Form 990 | 90-0658125 |
| Huntington's Disease Society of America | Audited Financial Statements | multiple |
|
Entity: Huntington's Disease Society of America Document Type: IRS Form 990 Tax ID: 13-3349872 |
|
Entity: Huntington's Disease Society of America Group Document Type: IRS Form 990 Tax ID: 90-0658125 |
|
Entity: Huntington's Disease Society of America Document Type: Audited Financial Statements Tax ID: multiple |
| Name | Title | Compensation | |
|---|---|---|---|
| 1 | Louise Vetter | CEO | $330,643 |
| 2 | George Yohrling | Senior Director, Mission & Scientific Affairs | $247,111 |
| 3 | Rosemary Coluccio | COO | $242,882 |
|
1 Name: Louise Vetter Title: CEO Compensation: $330,643 |
|
2 Name: George Yohrling Title: Senior Director, Mission & Scientific Affairs Compensation: $247,111 |
|
3 Name: Rosemary Coluccio Title: COO Compensation: $242,882 |
CharityWatch's rating of Huntington's Disease Society of America includes the financial activities of the Society's headquarters, based in New York City, and its 35 chapters located throughout the United States, which are included in the Society's audited financial statements for the year ended December 31, 2020. |
According to the Huntington's Disease Society of America audit of December 31, 2020 (Note M, Paycheck Protection Program Loan Payable): "On May 1, 2020, the Society received $634,692 in funds from JP Morgan Chase Bank and these proceeds are reported as a PPP loan payable on the [audited] statements of financial position as of December 31, 2020. Neither principal nor interest is due for a ten-month deferral period from the last day of the Society's covered period, which is October 15, 2021. This loan may be forgiven subject to bank approval in accordance with SBA [Small Business Administration] guidelines. Any outstanding principle of the loan that is not forgiven under the PPP loan program at the end of the ten-month deferral period will convert to a term loan with an interest rate of 0.98% payable in equal installments of principal and interest over the next twenty-four months, beginning February 2021. The loan matures on May 1, 2022. The Society is in the process of applying for forgiveness." |
According to the Huntington's Disease Society of America audit of December 31, 2020 (Note A-14, Donated goods and services), the Society received donated goods and services during 2020 on which it placed a total value of $132,439. [Note: CharityWatch generally excludes the value of in-kind (non-cash) donations of goods and services from its calculations of Program % and Cost to Raise $100. More information on how grades are calculated and the treatment of in-kind donations can be found on the Our Process page.] |
According to the Huntington's Disease Society of America audit of December 31, 2020 (Note J-3, Commitments, Contingency, and Other Uncertainty, Litigation): "The Society is a defendant in a legal action arising from the normal course of operations. Although the final outcome of such actions cannot currently be determined, the Society's management believes that the eventual liability, if any, will be covered by insurance." |
According to the Huntington's Disease Society of America audit of December 31, 2020 (Note J-2, Commitments, Contingency, and Other Uncertainty, Other uncertainty): "The extent of the impact of the COVID-19 outbreak on the Society's programming, operational and financial performance is uncertain and will depend on the continued future developments of the outbreak and external restrictions imposed. The potential impact brought by, and the duration of, the COVID-19 pandemic is difficult to assess or predict and may have an adverse impact on the Society's operations." |
